Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Piper Sandler

Piper Sandler started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Wednesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $12.00 price objective on the stock.

CMPX has been the subject of a number of other reports. D. Boral Capital reissued a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $5.00 to $4.00 in a report on Friday, November 15th. Jefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.29.

Compass Therapeutics Price Performance

Shares of CMPX opened at $3.38 on Wednesday. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.08. The company has a 50 day simple moving average of $2.37 and a two-hundred day simple moving average of $1.85. The firm has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers lifted its position in shares of Compass Therapeutics by 3.1% during the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after purchasing an additional 3,822 shares during the last quarter. Invesco Ltd. lifted its position in shares of Compass Therapeutics by 11.3% during the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after purchasing an additional 4,018 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after buying an additional 6,041 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after buying an additional 9,451 shares during the period. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.